Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Nemtabrutinib, a BTK inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chimeric antigen receptor (CAR) T-cell therapy, such as brexu-cel, is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Chemotherapy, such as fludarabine and cyclophosphamide, are given before CAR T cell therapy to help kill cancer cells in the body and help make room for the CAR T cells. Giving nemtabrutinib in combination with brexu-cel may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza chłoniaka płaszcza, który powrócił lub nie reaguje na leczenie
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ocena ECOG 0-2)
- •Zdolność połykania leków w postaci tabletek
- •Osoby z wirusem hepatitis B mogą uczestniczyć, jeśli otrzymują terapię przez co najmniej 4 tygodnie i mają niski poziom wirusa
- •Osoby z wirusem hepatitis C mogą uczestniczyć, jeśli wirus jest niewykrywalny i ukończyły leczenie co najmniej 4 tygodnie przed badaniem
- •Osoby z HIV mogą uczestniczyć, jeśli liczba CD4 wynosi co najmniej 350 komórek na mililitr krwi
- •Zgoda na udział w badaniu podpisana przez pacjenta lub jego przedstawiciela prawnego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Vanderbilt University/Ingram Cancer Center
Nashville, United States
Trial contact
Vanderbilt-Ingram Services for Timely Access
Vanderbilt-Ingram Services Timely Access
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.